# Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT06040424** · PHASE3 · UNKNOWN · sponsor: **Neutec Ar-Ge San ve Tic A.Ş** · enrollment: 74 (estimated)

## Conditions studied

- COPD

## Interventions

- **COMBINATION_PRODUCT:** Ipratropium / Levosalbutamol Fixed Dose Combination
- **DRUG:** Ipratropium + Levosalbutamol Free Dose Combination

## Key facts

- **NCT ID:** NCT06040424
- **Lead sponsor:** Neutec Ar-Ge San ve Tic A.Ş
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-28
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06040424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06040424, "Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06040424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*